Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III, inducing conformational change that accelerates its inhibition of thrombin (factor IIa), factor Xa, and other coagulation factors (IXa, XIa, XIIa).
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
Initial IV bolus of 80 units/kg followed by continuous IV infusion of 18 units/kg/hour; dose adjusted based on aPTT. Typical infusion range 10-30 units/kg/hour. Subcutaneous route: 5000 units every 8-12 hours for prophylaxis.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
30-150 minutes (dose-dependent: 0.5-1.5 h at low doses, up to 2.5 h at high doses). Prolonged in hepatic or renal impairment.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal (predominantly), with minor biliary/fecal elimination. Clearance is dose- and concentration-dependent due to saturable binding.
Category C
Category A/B
Anticoagulant
Anticoagulant